EdnanKBajwaMDMPH

Critical Care Medicine

MICU Director at Massachusetts General Hospital

Dr. Bajwa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-1721

Fax+1 617-726-6878

Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2007
Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
New York University School of MedicineClass of 2000

LIPS-A: Lung Injury Prevention Study With Aspirin Start of enrollment: 2012 Jan 01
Completed
Phase 2

PubMed

394 citations
Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.
Michael A. Matthay, Carolyn S. Calfee, Hanjing Zhuo, B. Taylor Thompson, Jennifer G. Wilson
The Lancet. Respiratory Medicine. 2019-02-01
42 citations
Prognostic and diagnostic value of plasma soluble suppression of tumorigenicity-2 concentrations in acute respiratory distress syndrome.
Ednan K. Bajwa, Jessica A. Volk, David C. Christiani, R. Scott Harris, Michael A. Matthay
Critical Care Medicine. 2013-11-01
8 citations
ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population.
Joseph W Rudolf, Elizabeth Lee Lewandrowski, Kent B. Lewandrowski, James L. Januzzi, Ednan K. Bajwa
American Journal of Clinical Pathology. 2016-02-01

Molecular Markers Of Risk, Phenotype, And Outcomes In ARDSNational Heart, Lung, And Blood Institute2008–2012